ArriVent BioPharma, Inc. (AVBP) intrinsic value & 10-year financials
ArriVent BioPharma, Inc. (AVBP) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $16.66
- Market cap
- $640.8M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 22.1%
- Free cash flow (FY2025)
- —
AVBP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$166.3M | -$4.32 | — | — | -90.7% |
| FY2024 | — | -$80.5M | -$2.56 | — | — | 134.1% |
| FY2023 | — | -$69.3M | -$2.16 | — | — | 22.9% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ArriVent BioPharma, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ArriVent BioPharma, Inc. has earned high returns on invested capital, averaging 22.1% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
ArriVent BioPharma, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
ArriVent BioPharma, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.